Humacyte (NASDAQ:HUMA) Stock Bumped Up to Hold by Barclays

Posted by Geri Gentry on Oct 8th, 2026

Barclays upgraded shares of Humacyte (NASDAQ:HUMA – Free Report) to a hold rating in a research report sent to investors on Wednesday,Zacks reports.

HUMA has been the subject of a number of other reports. Benchmark reduced their target price on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research note on Thursday, August 13th. Wall Street Zen lowered shares of Humacyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. HC Wainwright lifted their price target on Humacyte from $3.00 to $4.00 and gave the company a “buy” rating in a report on Thursday, June 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research report on Friday, October 2nd. Finally, TD Cowen decreased their price objective on Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a report on Wednesday, June 17th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Humacyte has a consensus rating of “Moderate Buy” and a consensus price target of $5.68.

Check Out Our Latest Report on Humacyte

Humacyte Stock Performance

HUMA stock opened at $0.47 on Wednesday. Humacyte has a 1 year low of $0.46 and a 1 year high of $1.90. The stock has a market capitalization of $131.20 million, a price-to-earnings ratio of -0.96 and a beta of 2.44. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21. The stock’s fifty day moving average is $0.61 and its two-hundred day moving average is $0.77.

Humacyte (NASDAQ:HUMA – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%.The firm had revenue of $0.41 million for the quarter, compared to the consensus estimate of $1.04 million. On average, research analysts predict that Humacyte will post -0.4 EPS for the current year.

Institutional Trading of Humacyte

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Alyeska Investment Group L.P. acquired a new position in Humacyte during the second quarter worth about $4,700,000. BlackRock Inc. bought a new position in shares of Humacyte during the 2nd quarter valued at about $3,777,000. GSA Capital Partners LLP acquired a new position in shares of Humacyte in the 2nd quarter worth approximately $785,000. HBK Investments L P bought a new position in shares of Humacyte in the second quarter valued at $617,000. Finally, Wealth Effects LLC acquired a new stake in shares of Humacyte during the 2nd quarter valued at $542,000. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

(Get Free Report)

Humacyte, Inc is a biotechnology company developing and manufacturing bioengineered human tissues for use in regenerative medicine. Its technology platform is designed to produce off-the-shelf, implantable tissues that can be stored and transported for use when needed, potentially reducing reliance on tissue obtained directly from patients or human donors.

The company’s primary product is SYMVESS, an acellular tissue-engineered vascular graft designed to replace or repair damaged blood vessels.